Better health.

Within reach.

Every day.

Meet the Management Series - Generics

September 2021

Disclaimer

Save to the extent required by law, neither Hikma Pharmaceuticals PLC nor any of its affiliates (Hikma), nor any other party, is under any duty to update or inform you of any changes to such

information. In particular, it should be noted that the financial information relating to Hikma contained in this document may not have been audited and in some cases is based on management information and estimates.

No reliance may be placed for any purposes whatsoever on the information contained in this document or on its completeness. No representation or warranty, express or implied, is given by or on behalf of Hikma or its directors, officers or employees, advisors or any other person as to the accuracy or completeness of the information or opinions contained in this document and no liability whatsoever is accepted for any such information or opinions or any use which may be made of them.

Certain statements in this presentation, are forward-looking statements, including under the US federal securities laws, including the Private Securities Litigation Reform Act of 1995. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Any forward-looking statements made by or on behalf of Hikma speak only as of the date they are made and are based upon the knowledge and information available to the directors on the date of this presentation.

Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Hikma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak as only of the date of this presentation.

By participating in, listening to or accessing this document or by accepting any copy of this document, you agree to be bound by the foregoing limitations.

All names, logos, and trademarks are properties of their respective owners and are used for identification purposes only.

Hikma Pharmaceuticals PLC

2

Agenda and speakers

2:00 -2:05pm

Welcome

Siggi Olafsson

2:05 -2:25pm

Business overview

Brian Hoffmann

2:25 -2:35pm

Operations and Quality

Mike Balog

2:35 -2:45pm

Commercial

Kristy Ronco

2:45 -2:50pm

Wrap up

Brian Hoffmann

2:50 -3:30pm

Q&A

All speakers

Siggi Olafsson

Brian Hoffmann

CEO

President

Kristy Ronco

Mike Balog

Chief Commercial

SVP Operations

Officer

Hikma Pharmaceuticals PLC

3

Generics - A high value, growing asset

Injectables

Generics

Branded

2020 revenue

42%

32%

26%

2020 core operating

57%

24%

19%

profit contribution1

1 Core operating profit is $566 million. Before unallocated corporate costs of $98 million and operating profit from Other business of zero, core operating profit contribution from business segments is $664 million.

Hikma Pharmaceuticals PLC

4

Business overview

Brian Hoffmann

President, Generics

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Hikma Pharmaceuticals plc published this content on 23 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 September 2021 13:31:04 UTC.